A Phase 1/2 interventional study of TP-122A in Pneumonia, Ventilator-Associated, sponsored by Technophage, SA. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-04-17.
Sponsored by Technophage, SA · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Pneumonia, Ventilator-Associated with a site in France — 20 open to participants now, 22 under way, 3 of them phase 3. Pneumonia, Ventilator-Associated · France.
Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, this one is the 44th largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 3 of the 21 other live ones, and was the 66th registered.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
Browse Pneumonia, Ventilator-Associated studies →20 of the 80 studies in Pneumonia, Ventilator-Associated with a site in France are open now. Recruiting first, the newest first:
Region Skane · Sites in France, Portugal, Sweden
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
University Hospital, Limoges · Sites in France
Ages 18+
Nantes University Hospital · Sites in France, Guadeloupe
Ages 18+
Centre Hospitalier Sud Francilien · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 17 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 115 across 276 interventional studies indexed under Pneumonia, Ventilator-Associated.
Median enrollment 161 across the 47 interventional studies, 268 across the 33 observational. Of the 49 that completed or were terminated, 7 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 80 have an industry lead sponsor. The 10 most frequent:
Technophage, SA is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Technophage, SA has 1 study filed under Pneumonia, Ventilator-Associated — fewer than ten, so there is no comparison to draw.
7 of the studies in Pneumonia, Ventilator-Associated with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05843786Phase 3Hospices Civils de LyonHuman Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients | 2027-07-30 |
| NCT06607055Centre Hospitalier Intercommunal Aix-PertuisImmunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia | 2026-12 |
| NCT05719259European Clinical Research Alliance for Infectious Diseases (ECRAID)Perpetual Observational Study - Ventilator Associated Pneumonia | 2026-12-01 |
| NCT06653933University Hospital, GrenobleStudy of Sleep Quality in the Intensive Care Unit and Association with Weaning from Invasive Ventilation in Patients with Chronic Obstructive Bronchopneumopathy. | 2027-02-01 |
| NCT05915663Centre Hospitalier le MansImpact of the Choice of Gastric Tube Placement Sites on the Incidence of Ventilator Associated Pneumonia | 2027-04-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Given the challenges of treating complex cases of VAP caused by P. aeruginosa and K. pneumoniae, TechnoPhage developed a bacteriophage cocktail (TP-122) against those pathogens, aiming to provide a hospital-based add-on therapy to the SoC including antibiotic therapy, administered by nebulization. TP-122 is a bacteriophage cocktail divided in two different components: TP-122A is comprised of three bacteriophages against infections caused by Pseudomonas aeruginosa and TP-122B includes three bacteriophages against K. pneumoniae . For this study, an effective sample of 15 subjects will be randomly allocated into two arms, in a 3:2 ratio, with 9 subjects receiving TP-122A, in addition to SoC, and 6 subjects receiving the SoC alone.
This is a randomized, parallel, open label, Phase 1/2a study, to assess the safety and tolerability of multiple doses of the component A of the bacteriophage cocktail TP-122 (TP-122A) administered by nebulization in addition to SoC, compared to SoC alone, in adult subjects with VAP. SoC being defined as the treatment dispensed in ICU by the medical team in their usual manner, which will include antibiotic treatment according to current guidelines.
Enrolled subjects randomized to TP-122A arm will receive 5 ml of IP by nebulization, every 8 hours, during 7 days, and will be followed-up for 28 days after the last IP administration.
TP-122 is a bacteriophage cocktail divided in two different components: TP-122A is comprised of three bacteriophages against infections caused by Pseudomonas aeruginosa and TP-122B includes three bacteriophages against K. pneumoniae . B This study will exclusively focus on assessing the safety and effectiveness of component A, TP-122A, specifically targeting infections caused by P. aeruginosa. The IP, TP-122A, will be administered by nebulization at 1x1010 Plaque Forming Units (PFU)/ml every 8h during 7 days, in addition to SoC, for the treatment of adult subjects with VAP due to P. aeruginosa. The decision to go for a frequency of administration of every 8 hours was firstly based on preclinical studies. TP-122A is composed of three lytic bacteriophages targeting P. aeruginosa.
An estimated total of 15 evaluable subjects are expected to complete the study. "Evaluable patients" will be considered subjects that have received at least a total of 9 IP administrations for three consecutive days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Able and willing to sign the ICF. If the subject is unable to do so, the family, a trusted person or a relative should provide consent, as per local regulations.
AND at least one of the following:
i. Hypoxemia [e.g., PaO2\<60 mmHg while the patient is breathing room air, as determined by Arterial Blood Gas (ABG), or worsening of PaO2/FiO2]; and/or ii. Need for acute changes in the ventilator support system to enhance oxygenation, as determined by worsening oxygenation (need to increase FiO2 by 20% or more to maintain oxygen saturation), or needed changes in the amount of PEEP; and/or iii. New onset of suctioned respiratory secretions.
AND at least one of the following signs:
iv. Documented fever (i.e., core body temperature [tympanic, rectal, esophageal] ≥ 38° C [100.4ºF], oral temperature ≥ 37.5°C [99.5ºF], or axillary temperature ≥ 37°C [98.6ºF]); and/or v. Hypothermia (i.e., core body temperature [tympanic, rectal, esophageal] ≤ 35°C [95°F]); and/or vi. White Blood Cell (WBC) count ≥ 10,000 cells/mm³; and/or vii. Leukopenia with total WBC count ≤ 4500 cells/mm³; and/or viii. Greater than 15% immature neutrophils (bands) noted on peripheral blood smear.
Diagnosis: cultures obtained by Endotracheal Aspirates (ETA), Mini Bronchoalveolar Lavage (BAL) or standard BAL throughout fiberoptic bronchoscopy, subjected to Gram staining and/or Polymerase Chain Reaction (PCR) test (e.g., BIOFIRE® FILMARRAY® Pneumonia Panel plus (Biomerieux)).
Exclusion Criteria:
History of any cancer requiring systemic chemotherapy or radiation, in the 5 previous years.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled subjects in the TP-122A+SoC arm will receive IP every 8 hours for 7 days by nebulization and will be followed-up for 28 days after the last IP administration.
Biological: TP-122A
Just standard of care will be given to patient
Bacteriophage cocktail targeting Psa
Evaluate safety and tolerability following nebulization of multiple doses of TP-122A
Analysis of TP-122A arm with SoC versus SoC alone, and individual analysis per treatment arm of the following assessments: Adverse Events (AEs): 1. Incidence of Treatment-Emergent Adverse Events (TEAEs). 2. Incidence of serious TEAEs. Note: including assessment of seriousness, severity, causality, and outcome.
Time frame: Day 0, 3 and Day 7
Proportion of subjects achieving "Clinical Cure" CR
Time frame: dosing days (1 to 7) and FUp1).
Time to achieve "Clinical Cure" CR
Time frame: Baseline to EOT
Proportion of subjects achieving "Eradication" or "Presumed Eradication" MR of TP-122A target bacteria
Time frame: dosing days (1 to 7), FUp1 and FUp2
Time to achieve "Eradication" or "Presumed Eradication" MR
Time frame: Day o and Day 7
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Sep 2024; primary completion for May 2025, 8 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated →
Technophage, SA